Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06528093 · ClinicalTrials.gov registry record · Phase 1
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06528093 is a Phase 1 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 8 participants.
The verdict
NCT06528093, a Phase 1 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is open to adults with advanced pancreatic cancer for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find the highest dose of BI 765883 that people with advanced pancreatic cancer can tolerate when taken alone or together with chemotherapy. Another purpose is to check whether BI 765883 helps people with advanced pancreatic cancer. In this study, BI 765883 is given to humans for the first time. Participants receive either BI 765883 alone or BI 765883 in combination with chemotherapy. Participants can stay in the study as long as they benefit from treatment and can tolerate it. At study visits, doctors collect information on any health problems of the participants and check the severity of participants' cancer.
Interventions
- DRUG nab-paclitaxel
- DRUG gemcitabine
- DRUG BI 765883
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2025-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06528093
The ClinicalTrials.gov registry entry for NCT06528093 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nab-paclitaxel is the first listed.
NCT06528093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06528093 about?
NCT06528093 is a clinical study titled "A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy". This study is open to adults with advanced pancreatic cancer for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find the highest dose of BI 765883 that people with advanced pancreatic cancer can tolerate when taken alone or together with chemother...
What is the current status of trial NCT06528093?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-10-16. Estimated completion is 2025-06-19.
What interventions are being tested in trial NCT06528093?
The interventions under investigation include: nab-paclitaxel (DRUG), gemcitabine (DRUG), BI 765883 (DRUG).
Who is sponsoring clinical trial NCT06528093?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.